AVXL · XBRL financial data

Anavex Life Sciences financial statements, every quarter

The same tables from 13 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (AVXL's year ends in late September)

In millions of dollars	Q4 FY23Sep 30, 2023	Q1 FY24Dec 31, 2023	Q2 FY24Mar 31, 2024	Q3 FY24Jun 30, 2024	Q4 FY24Sep 30, 2024	Q1 FY25Dec 31, 2024	Q2 FY25Mar 31, 2025	Q3 FY25Jun 30, 2025	Q4 FY25Sep 30, 2025	Q1 FY26Dec 31, 2025	Q2 FY26Mar 31, 2026	Q3 FY26Jun 30, 2026
Research and development	10*	9	10	12	12*	10	10	10	7*	5	4	—
Selling, general and administrative	year only	—	—	—	year only	3	3	5	4*	2	2	2
General and administrative	3*	3	3	3	3*	3	3	5	4*	2	2	—
Total operating expenses	13*	11	13	15	14*	14	13	14	11*	7	6	(7)
Operating income (loss)	(13)*	(11)	(13)	(15)	(14)*	(14)	(13)	(14)	(11)*	(7)	(6)	7
Income tax expense (benefit)	—	—	—	—	—	—	—	—	—	0	0*	0*
Net income (loss)	(10)*	(9)	(11)	(12)	(12)*	(12)	(11)	(13)	(10)*	(6)	(5)	8
Earnings per share, basic USD per share	(0.12)*	(0.11)	(0.13)	(0.14)	(0.14)*	(0.14)	(0.13)	(0.16)	(0.11)*	(0.06)	(0.06)	0.08
Earnings per share, diluted USD per share	(0.12)*	(0.11)	(0.13)	(0.14)	(0.14)*	(0.14)	(0.13)	(0.16)	(0.11)*	(0.06)	(0.06)	0.08
Weighted average shares, basic millions of shares	82*	82	82	85	85*	85	85	85	86*	89	93	92,697
Weighted average shares, diluted millions of shares	82*	82	82	85	85*	85	85	85	86*	89	93	92,900

Fiscal quarters (AVXL's year ends in late September)

In millions of dollars	Q4 FY23Sep 30, 2023	Q1 FY24Dec 31, 2023	Q2 FY24Mar 31, 2024	Q3 FY24Jun 30, 2024	Q4 FY24Sep 30, 2024	Q1 FY25Dec 31, 2024	Q2 FY25Mar 31, 2025	Q3 FY25Jun 30, 2025	Q4 FY25Sep 30, 2025	Q1 FY26Dec 31, 2025	Q2 FY26Mar 31, 2026	Q3 FY26Jun 30, 2026
Cash and cash equivalents	151	144	139	139	132	121	116	101	103	132	127	118
Prepaid and other current assets	1	1	1	1	1	1	1	0	0	0	0	1
Total assets	154	148	145	142	136	124	117	102	104	133	129	120
Accounts payable	4	4	4	4	10	5	7	7	4	3	3	4
Accrued liabilities	7	7	5	7	5	8	10	4	4	3	4	4
Total liabilities	13	12	10	12	15	13	17	11	9	6	7	8
Accumulated deficit	(293)	(302)	(312)	(324)	(336)	(348)	(359)	(373)	(382)	(388)	(393)	(386)
Total stockholders' equity	142	136	135	130	120	111	100	91	95	127	122	112
Total liabilities and equity	154	148	145	142	136	124	117	102	104	133	129	120
Common shares outstanding (cover page) millions of shares	82	82	85	85	85	85	85	86	89	93	93	93

Fiscal quarters (AVXL's year ends in late September)

In millions of dollars	Q4 FY23Sep 30, 2023	Q1 FY24Dec 31, 2023	Q2 FY24Mar 31, 2024	Q3 FY24Jun 30, 2024	Q4 FY24Sep 30, 2024	Q1 FY25Dec 31, 2024	Q2 FY25Mar 31, 2025	Q3 FY25Jun 30, 2025	Q4 FY25Sep 30, 2025	Q1 FY26Dec 31, 2025	Q2 FY26Mar 31, 2026	Q3 FY26Jun 30, 2026
Net income (loss)	(10)*	(9)	(11)	(12)	(12)*	(12)	(11)	(13)	(10)*	(6)	(5)	8
Stock-based compensation	3*	2	3	2	2*	2	1	4	4*	1	0	(17)
Net cash from operating activities	(6)*	(7)	(12)*	(5)*	(7)*	(12)	(6)*	(12)*	(9)*	(7)	(4)*	(9)*
Proceeds from issuing common stock	1*	—	—	4*	0*	—	—	—	—	—	—	—
Net cash from financing activities	2*	0	7*	5*	0*	1	1*	(2)*	10*	36	0*	0*

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Anavex Life Sciences	118	not reported	(9.1)*	92.7M	13.0 quarters	Q3 FY26 10-QJun 30, 2026
ImmunityBio	76	51	(66)*	1.1B	5.4 quarters	Q2 FY26 10-QJun 30, 2026
Immunome	218	0	(62)*	113.6M	8.4 quarters	Q2 FY26 10-QJun 30, 2026
Pacira BioSciences	206	192	57*	39.9M	—	Q2 FY26 10-QJun 30, 2026
Phibro Animal Health	61	397*	24*	not reported	—	Q4 FY26 10-KJun 30, 2026
uniQure	98	5.2	(48)*	70.1M	2.6 quarters	Q3 FY26 10-QSep 30, 2026
Cogent Biosciences	181	not reported	(77)*	173.5M	10.3 quarters	Q2 FY26 10-QJun 30, 2026
Anaptysbio	134	27*	(27)*	29.9M	6.2 quarters	Q4 FY26 10-KTJun 30, 2026
Amphastar Pharmaceuticals	224	184	51*	42.5M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.